ETF Holdings Breakdown of BNTX

BNTX institutional holdings

The adjusted close for BNTX on 2026-01-13 was 107.19

The following institutional investment holdings of BNTX have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2026-01-13	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	1,595 0.2%	USD 170,968 4.9%	107.19
2026-01-13	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	68,693	USD 7,363,203 4.7%	107.19
2026-01-13	IE00BG13YL86 (iShares Edge MSCI Europe Multifactor UCITS ETF EUR (Dist) USD)	3,123	USD 287,318 4.9%	92.00 Incorrect share price reported. Should be 107.19 not 92.00. May be due to incorrect reporting of currency . Could be EUR or USD instead	IE00BG13YL86 incorrectly reporting value of holding as USD actually is reported in EUR
2026-01-13	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	68,693	USD 7,363,203 4.7%	107.19
2026-01-13	IE00BZ0PKV06 (iShares STOXX Europe Equity Multifactor UCITS ETF EUR (Acc))	3,123	USD 287,318 4.9%	92.00 Incorrect share price reported. Should be 107.19 not 92.00. May be due to incorrect reporting of currency . Could be EUR or USD instead	IE00BZ0PKV06 incorrectly reporting value of holding as USD actually is reported in EUR
2026-01-12	IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc)	403 1.0%	USD 41,179 3.3%	102.18 Incorrect share price reported. Should be 107.19 not 102.18. May be due to incorrect reporting of currency . Could be EUR or USD instead
Total =		145,630	USD 15,513,189

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with BNTX

HC Wainwright Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)

HC Wainwright restated their buy rating on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Monday,Benzinga reports. They currently have a $136.00 price target on the stock. BNTX has been the subject of several other research reports. Bank of America increased their price objective on shares of BioNTech from $126.00 to […] - 2025-09-09 02:50:43

HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX – Free Report) had its target price lowered by HC Wainwright from $138.00 to $136.00 in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. BNTX has been the subject of a number of other research reports. The Goldman Sachs Group began coverage […] - 2025-08-15 04:24:50

BioNTech (NASDAQ:BNTX) Given a $150.00 Price Target by Wells Fargo & Company Analysts

BioNTech (NASDAQ:BNTX – Get Free Report) has been assigned a $150.00 price target by Wells Fargo & Company in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 34.77% from […] - 2025-08-07 04:38:47

TD Asset Management Inc Trims Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

TD Asset Management Inc lowered its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 74.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,452 shares of the company’s stock after selling 32,530 shares during the quarter. TD Asset Management Inc’s holdings […] - 2025-08-05 04:37:23

Envestnet Asset Management Inc. Trims Holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Envestnet Asset Management Inc. decreased its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 57.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,762 shares of the company’s stock after selling 11,715 shares during the quarter. Envestnet Asset […] - 2025-08-04 06:31:06

Notable Two Hundred Day Moving Average Cross - BNTX

In trading on Thursday, shares of BioNTech SE (Symbol: BNTX) crossed below their 200 day moving average of $108.91, changing hands as low as $107.69 per share. BioNTech SE shares are currently trading off about 0.6% on the day. The chart below shows the one year performance of - 2025-07-31 14:28:08

Pfizer, BioNTech Receive Positive CHMP Opinion For LP.8.1-adapted COVID-19 Vaccine

(RTTNews) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) Friday said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies' LP.8.1-adapted COVID-19 vaccine, COMIRNATY LP.8.1, for use - 2025-07-25 03:57:25

Robeco Institutional Asset Management B.V. Sells 23,873 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX)

Robeco Institutional Asset Management B.V. cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 23.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 77,535 shares of the company’s stock after selling 23,873 shares during the […] - 2025-06-30 05:06:52

HC Wainwright Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX – Get Free Report) had its price target lowered by investment analysts at HC Wainwright from $145.00 to $138.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 31.47% from the company’s current […] - 2025-06-18 02:22:53

HC Wainwright Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX – Free Report) had its price target upped by HC Wainwright from $134.00 to $145.00 in a research note released on Thursday, Marketbeat reports. The brokerage currently has a buy rating on the stock. Other equities analysts also recently issued reports about the stock. BMO Capital Markets increased their price target on shares […] - 2025-06-06 04:58:53

Truist Financial Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Truist Financial in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $155.00 price objective on the stock, up from their previous price objective of $151.00. Truist Financial’s price objective suggests a potential upside of 39.46% […] - 2025-06-05 02:44:47

BioNTech SE (NASDAQ:BNTX) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp lowered its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 83.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,903 shares of the company’s stock after selling 19,370 shares during the quarter. […] - 2025-06-04 05:19:00

BioNTech (NASDAQ:BNTX) versus Silexion Therapeutics (NASDAQ:SLXN) Financial Survey

BioNTech (NASDAQ:BNTX – Get Free Report) and Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Risk & Volatility BioNTech has a beta of 1.35, […] - 2025-05-28 03:06:56

BioNTech SE (NASDAQ:BNTX) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC cut its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 19.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,652 shares of the company’s stock after selling 1,141 shares during the period. ProShare Advisors LLC’s holdings in […] - 2025-05-27 04:52:56

Analysts Set BioNTech SE (NASDAQ:BNTX) Target Price at $142.08

Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are currently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy […] - 2025-05-26 04:40:55

BioNTech SE (NASDAQ:BNTX) Shares Purchased by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co boosted its position in BioNTech SE (NASDAQ:BNTX – Free Report) by 63.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,791 shares of the company’s stock after purchasing an additional 3,025 shares during the quarter. CANADA LIFE ASSURANCE Co’s […] - 2025-04-30 04:59:01

FNDF, MDT, BNTX, FERG: ETF Inflow Alert

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab Fundamental International Large Company Index (Symbol: FNDF) where we have detected an approximate $136.9 million dollar inflow -- that's a 0. - 2025-04-28 12:09:26

Invesco Ltd. Lowers Holdings in BioNTech SE (NASDAQ:BNTX)

Invesco Ltd. lowered its position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 1.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 86,753 shares of the company’s stock after selling 1,005 shares during the period. Invesco Ltd.’s holdings in BioNTech were worth $9,886,000 as of its most recent filing with […] - 2025-04-23 05:58:48

LPL Financial LLC Has $4.43 Million Stake in BioNTech SE (NASDAQ:BNTX)

LPL Financial LLC grew its holdings in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 4.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 38,860 shares of the company’s stock after acquiring an additional 1,800 shares during the quarter. LPL Financial LLC’s holdings in BioNTech were worth $4,428,000 as of its most recent […] - 2025-04-10 04:38:48

Arrowstreet Capital Limited Partnership Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Arrowstreet Capital Limited Partnership acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,827 shares of the company’s stock, valued at approximately $3,513,000. A number of […] - 2025-04-09 05:26:59

Mitsubishi UFJ Asset Management Co. Ltd. Has $265,000 Stake in BioNTech SE (NASDAQ:BNTX)

Mitsubishi UFJ Asset Management Co. Ltd. reduced its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 20.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,285 shares of the company’s stock after selling 572 shares during the quarter. Mitsubishi UFJ Asset Management Co. […] - 2025-04-04 05:19:13

HC Wainwright Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 55.38% from the stock’s current price. A […] - 2025-04-03 02:54:45

BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Citigroup

Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target price on the stock. Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. cut their price target on shares […] - 2025-03-14 06:26:54

BMO Capital Markets Increases BioNTech (NASDAQ:BNTX) Price Target to $143.00

BioNTech (NASDAQ:BNTX – Get Free Report) had its price target boosted by investment analysts at BMO Capital Markets from $130.00 to $143.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. BMO Capital Markets’ target price indicates a potential upside of 42.56% from the company’s current price. […] - 2025-03-13 04:25:02

Canaccord Genuity Group Reiterates “Buy” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $171.44 price objective on the stock. Canaccord Genuity Group’s price target points to a potential upside of 70.91% from the company’s previous close. A […] - 2025-03-13 04:25:00

SVB Wealth LLC Buys Shares of 1,788 BioNTech SE (NASDAQ:BNTX)

SVB Wealth LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm bought 1,788 shares of the company’s stock, valued at approximately $204,000. A number of other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. […] - 2025-03-07 08:05:05

BioNTech SE (NASDAQ:BNTX) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 10.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,513 shares of the company’s stock after selling 418 shares during the period. Mirae Asset […] - 2025-02-13 06:32:55

BioNTech SE (NASDAQ:BNTX) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp cut its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 26.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 414 shares of the company’s stock after selling 148 shares during the quarter. Fifth Third Bancorp’s holdings in BioNTech […] - 2025-02-03 06:28:57

Back to Listing

Disclaimer

Copyright Market Footprint Ltd. Privacy Policy